The dysregulation of MALAT1 has been linked to poor prognosis in breast cancer, where its upregulation activates oncogenic pathways such as PI3K/AKT, Wnt/β‐catenin, and STAT3, leading to increased proliferation, survival, and therapeutic evasion [47, 49–51]. This evidence concerns the gene STAT3 and breast carcinoma.